[1] |
SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
|
[2] |
CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
|
[3] |
ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.
|
[4] |
LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. DOI: 10.1038/s41572-020-00240-3.
|
[5] |
CHEN L, FLIES DB. Molecular mechanisms of T cell co-stimulation and co-inhibition[J]. Nat Rev Immunol, 2013, 13(4): 227-242. DOI: 10.1038/nri3405.
|
[6] |
HE X, XU C. Immune checkpoint signaling and cancer immunotherapy[J]. Cell Res, 2020, 30(8): 660-669. DOI: 10.1038/s41422-020-0343-4.
|
[7] |
YAU T, PARK J W, FINN R S, et al. CheckMate 459: A randomized, multi-center phase Ⅲ study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) [J]. Ann Oncol, 2019, 30: v874-v875. DOI: 10.1093/annonc/mdz394.029
|
[8] |
FINN RS, RYOO BY, MERLE P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(3): 193-202. DOI: 10.1200/JCO.19.01307.
|
[9] |
ZHU XD, LI KS, SUN HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects[J]. Genes Dis, 2020, 7(3): 359-369. DOI: 10.1016/j.gendis.2020.02.002.
|
[10] |
SUN HC. Conversion surgery for unresectable or advanced hepatocellular carcinoma[J]. J Abdominal Surg, 2021, 34(2): 85-87. DOI: 10.3969/j.issn.1003-5591.2021.02.001.
孙惠川. 不可切除和中晚期肝癌的转化切除[J]. 腹部外科, 2021, 34(2): 85-87. DOI: 10.3969/j.issn.1003-5591.2021.02.001.
|
[11] |
PINATO DJ, FESSAS P, SAPISOCHIN G, et al. Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma[J]. Hepatology, 2021, 74(1): 483-490. DOI: 10.1002/hep.31697.
|
[12] |
MILLER BC, SEN DR, AL ABOSY R, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade[J]. Nat Immunol, 2019, 20(3): 326-336. DOI: 10.1038/s41590-019-0312-6.
|
[13] |
LIU J, O'DONNELL JS, YAN J, et al. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome[J]. Oncoimmunology, 2019, 8(5): e1581530. DOI: 10.1080/2162402X.2019.1581530.
|
[14] |
YARCHOAN M, ZHU Q, DURHAM J N, et al. Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC) [J]. J Clin Oncol, 2021, 39(3_suppl): 335. DOI: 10.1200/JCO.2021.39.3_suppl.335
|
[15] |
XIA Y, WANG P, PU L, et al. Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase Ⅱ study [J]. J Clin Oncol, 2021, 39(15_suppl): 4082. DOI: 10.1200/JCO.2021.39.15_suppl.4082
|
[16] |
KASEB AO, HASANOV E, CAO H, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 208-218. DOI: 10.1016/S2468-1253(21)00427-1.
|
[17] |
YU YQ, TANG ZY, ZHOU XD, et al. Staged treatment of large hepatocellular carcinoma [J]. Chin J Surg, 1983, 21(2): 92-93. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201906049.htm
余业勤, 汤钊猷, 周信达, 等. 大肝癌的分阶段治疗[J]. 中华外科杂志, 1983, 21(2): 92-93. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201906049.htm
|
[18] |
ZHU XD, HUANG C, SHEN YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J]. Liver Cancer, 2021, 10(4): 320-329. DOI: 10.1159/000514313.
|
[19] |
ZHANG W, HU B, HAN J, et al. Surgery after conversion therapy with PD-1 inhibitors plus tyrosine kinase inhibitors are effective and safe for advanced hepatocellular carcinoma: A pilot study of ten patients[J]. Front Oncol, 2021, 11: 747950. DOI: 10.3389/fonc.2021.747950.
|
[20] |
YANG X, XU H, ZUO B, et al. Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy[J]. Hepatobiliary Surg Nutr, 2021, 10(4): 434-442. DOI: 10.21037/hbsn-21-188.
|
[21] |
ZHANG J, ZHANG X, MU H, et al. Surgical conversion for initially unresectable locally advanced hepatocellular carcinoma using a triple combination of angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy: A retrospective study[J]. Front Oncol, 2021, 11: 729764. DOI: 10.3389/fonc.2021.729764.
|
[22] |
KRALL JA, REINHARDT F, MERCURY OA, et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy[J]. Sci Transl Med, 2018, 10(436): eaan3464. DOI: 10.1126/scitranslmed.aan3464.
|
[23] |
ISHIKAWA M, NISHIOKA M, HANAKI N, et al. Perioperative immune responses in cancer patients undergoing digestive surgeries[J]. World J Surg Oncol, 2009, 7: 7. DOI: 10.1186/1477-7819-7-7.
|
[24] |
D
|
[25] |
KUDO M. Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis, ASCO Annual Meeting, F, 2021[C]. American Society of Clinical Oncology.
|
[26] |
YANG X, SUN H, HU B, et al. 944P Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC Ⅱ and Ⅲ stage: A single-center prospective phase Ⅱ trial [J]. Annals Oncol, 2021, 32: S824.
|
[27] |
DUAN J, CUI L, ZHAO X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: A systematic review and meta-analysis[J]. JAMA Oncol, 2020, 6(3): 375-384. DOI: 10.1001/jamaoncol.2019.5367.
|
[28] |
BERTRAND A, KOSTINE M, BARNETCHE T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis[J]. BMC Med, 2015, 13: 211. DOI: 10.1186/s12916-015-0455-8.
|
[29] |
ZHU A X, FINN R S, IKEDA M, et al. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)[J]. J Clin Oncol, 2020, 38(15_suppl): 4519. DOI: 10.1200/JCO.2020.38.15_suppl.4519
|
[30] |
XU B, SUN HC. Camrelizumab: An investigational agent for hepatocellular carcinoma[J]. Expert Opin Investig Drugs, 2021: 1-10. DOI: 10.1080/13543784.2022.2022121.
|
[31] |
SANGRO B, CHAN SL, MEYER T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma[J]. J Hepatol, 2020, 72(2): 320-341. DOI: 10.1016/j.jhep.2019.10.021.
|
[32] |
SHI GM, HUANG XY, REN ZG, et al. Chinese expert consensus on the management of immune-related adverse events of hepato-cellular carcinoma treated with immune checkpoint inhibitors (2021 edition)[J]. Chin J Dig Surg, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.
施国明, 黄晓勇, 任正刚, 等. 肝癌免疫检查点抑制剂相关不良反应管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.
|